Willner & Heller LLC Buys Shares of 379 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Willner & Heller LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 379 shares of the biopharmaceutical company’s stock, valued at approximately $333,000.

Other institutional investors also recently bought and sold shares of the company. Stifel Financial Corp raised its holdings in Regeneron Pharmaceuticals by 12.2% in the 3rd quarter. Stifel Financial Corp now owns 31,030 shares of the biopharmaceutical company’s stock valued at $25,537,000 after buying an additional 3,385 shares during the period. LPL Financial LLC increased its position in shares of Regeneron Pharmaceuticals by 9.3% during the third quarter. LPL Financial LLC now owns 40,733 shares of the biopharmaceutical company’s stock valued at $33,522,000 after acquiring an additional 3,479 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $749,000. Public Employees Retirement Association of Colorado lifted its holdings in shares of Regeneron Pharmaceuticals by 16.0% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after acquiring an additional 2,220 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock worth $4,351,000 after acquiring an additional 1,221 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. Evercore ISI started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Royal Bank of Canada lifted their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,229.00 and gave the company an “outperform” rating in a report on Wednesday. UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Finally, Bank of America boosted their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $991.18.

View Our Latest Stock Analysis on REGN

Insider Buying and Selling at Regeneron Pharmaceuticals

In related news, Director Michael S. Brown sold 1,172 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Michael S. Brown sold 1,172 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Leonard S. Schleifer sold 9,064 shares of the stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $1,015.43, for a total transaction of $9,203,857.52. Following the completion of the sale, the chief executive officer now owns 55,134 shares in the company, valued at $55,984,717.62. The disclosure for this sale can be found here. Over the last three months, insiders sold 59,680 shares of company stock valued at $58,818,382. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN traded up $9.97 during mid-day trading on Friday, hitting $1,036.52. 353,915 shares of the company’s stock were exchanged, compared to its average volume of 364,879. The business’s 50 day moving average is $956.29 and its two-hundred day moving average is $936.53. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $114.21 billion, a P/E ratio of 30.62, a P/E/G ratio of 2.14 and a beta of 0.13. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $1,042.66.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The firm had revenue of $3.15 billion during the quarter, compared to analyst estimates of $3.19 billion. On average, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNFree Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.